Antisense drug ION224 reverses liver fibrosis in MASH trial
The syringe held a clear liquid. It looked like water. But inside that monthly injection was a tiny piece of genetic code, designed to do one thing: silence a single enzyme inside a human liver.
Dr. Rohit Loomba watched the first patient receive the dose at the University of California San Diego School of Medicine [1]. The room was quiet. The patient did not feel anything. No heat, no rush, no change. For 51 weeks, 160 adults across the United States would receive this same injection or a placebo. None of them knew which group they were in.
The disease they carried was invisible. It had no early symptoms. No pain. No warning. But inside their livers, fat was building up. Cells were becoming inflamed. Scar tissue was slowly, quietly replacing healthy tissue. This condition, called MASH, or metabolic dysfunction-associated steatohepatitis, affects more than 100 million people in the United States alone. Most of them do not know they have it.
Dr. Loomba and his team at UC San Diego were testing a drug called ION224 [2]. It was not a pill. It was not a hormone. It was an antisense oligonucleotide — a short, synthetic strand of DNA that binds to the messenger RNA of a specific gene and stops it from working. The target was an enzyme called DGAT2.
This enzyme acts like a factory foreman inside liver cells. It takes fatty acids and turns them into triglycerides, the main form of fat stored in the liver. When the foreman works too hard, the factory overproduces. Fat spills out of storage and begins to damage the machinery itself. Inflammation starts. Scarring begins. The liver slowly hardens.
Scientists have known about DGAT2 for years. In 2006, researchers at the University of Texas Southwestern Medical Center first identified its role in liver fat production [3]. They showed that mice lacking the DGAT2 gene had almost no fat in their livers, even when fed high-fat diets. But turning off that gene in humans was a different challenge entirely.
The problem was precision. Early drugs that tried to block fat production in the liver often caused dangerous side effects. One class of drugs, called DGAT1 inhibitors, caused severe diarrhea and weight loss. Another approach, using small molecules to block DGAT2, led to dangerously high triglyceride levels in the blood. The liver would compensate by dumping fat into the bloodstream instead of storing it.
ION224 was different. It did not block the enzyme directly. Instead, it prevented the enzyme from being made in the first place. The antisense technology, developed by Ionis Pharmaceuticals, works like a lock and key at the genetic level [4]. The drug enters liver cells and binds to the messenger RNA that carries the instructions for building DGAT2. Once bound, the RNA is destroyed. The factory foreman never gets built.
The Moment the Data Changed Everything
The trial ran for 51 weeks. Patients came in monthly for their injections. They gave blood samples. They underwent liver biopsies. They filled out questionnaires about how they felt.
Most of them felt fine. That was expected. MASH does not announce itself. A person can have significant liver damage and still feel healthy. The only way to know if the drug was working was to look at the numbers.
When the data from the Phase IIb clinical trial was unblinded, the researchers saw something they had not expected. Patients receiving the highest dose of ION224 showed 60% improvement in liver health compared to those on placebo. The improvement was measured using a standard called the NAFLD Activity Score, which grades fat accumulation, inflammation, and ballooning of liver cells.
But the most striking finding came from the fibrosis data. Fibrosis is the scarring of liver tissue. It is the step that turns fatty liver into cirrhosis. Reversing fibrosis has been the holy grail of MASH research for two decades. Previous drugs had failed. Some had caused heart problems. Others had triggered liver toxicity. A few had shown modest results but only when patients lost significant weight.
ION224 improved fibrosis without weight loss. Patients did not need to change their diet. They did not need to exercise more. The drug worked inside their livers, independent of what was happening in the rest of their bodies.
Dr. Loomba presented the findings at a medical conference in San Diego in early 2026 [2]. The room was filled with hepatologists, endocrinologists, and pharmaceutical executives. When the slides showing the fibrosis data appeared, there was a pause. Then people started typing on their phones.
This was the first time an antisense therapy targeting DGAT2 had shown real biological impact in humans with MASH.
The Quiet Epidemic
To understand why this matters, you have to understand how MASH became one of the most common diseases in the world.
In 1980, fatty liver disease was rare. Most doctors never saw it. The condition was considered a curiosity, something that happened to heavy drinkers or people with rare genetic disorders.
Then came the obesity epidemic.
By 2020, an estimated one in four adults globally had some form of fatty liver disease. The numbers were staggering. In the United States, the prevalence of MASH, the aggressive form of the disease, was estimated at 3% to 5% of the population. Among people with type 2 diabetes, that number jumped to 20%.
The disease progresses in stages. First, fat accumulates in liver cells. This stage, called steatosis, is reversible. The liver can clear the fat if the person loses weight or changes their diet. But if the fat stays, inflammation begins. Immune cells enter the liver. They try to repair the damage but end up causing more harm. This is steatohepatitis, or MASH.
Over time, the liver tries to protect itself by forming scar tissue. This is fibrosis. The scar tissue builds up slowly, year after year. At stage F1, the scarring is mild. At stage F2, it is moderate. At stage F3, it is severe. At stage F4, the liver is completely scarred. This is cirrhosis.
Once cirrhosis develops, the risk of liver failure and liver cancer skyrockets. The only treatment for end-stage liver disease is transplantation. But there are not enough donor livers. In 2024, more than 10,000 people in the United States were waiting for a liver transplant. Hundreds die each year before a liver becomes available.
The tragedy is that most of these deaths could have been prevented if the disease had been caught early. But early MASH has no symptoms. A person can have F3 fibrosis and still feel perfectly healthy. The first sign of trouble might be jaundice, abdominal swelling, or confusion caused by toxins building up in the blood. By then, the damage is often irreversible.
The Search for the Root Cause
For decades, the medical establishment focused on treating the symptoms of fatty liver disease rather than the cause. Patients were told to lose weight. They were told to exercise. They were given medications for diabetes and high cholesterol. But no drug existed that directly targeted the fat buildup in the liver.
The turning point came in the early 2010s, when researchers at the National Institutes of Health and several academic medical centers began mapping the metabolic pathways involved in liver fat production [5]. They identified two key enzymes: DGAT1 and DGAT2.
Both enzymes perform the same chemical reaction. They take a molecule called diacylglycerol and add a third fatty acid to create triacylglycerol, or fat. But they do it in different places in the cell. DGAT1 works near the surface of the cell, where fat is packaged for export. DGAT2 works deep inside the cell, where fat is stored for energy.
When scientists at UT Southwestern created mice that lacked DGAT2, the animals had almost no fat in their livers [3]. But they also had trouble surviving. The enzyme was essential for life. Blocking it completely was not an option.
The solution was partial inhibition. Antisense technology allowed researchers to reduce DGAT2 levels by about 70% to 80% rather than eliminating them entirely. This was enough to stop fat buildup without causing fatal side effects.
Ionis Pharmaceuticals, based in Carlsbad, California, had been working on antisense therapies for decades [4]. The company had already developed drugs for rare genetic diseases like spinal muscular atrophy and familial chylomicronemia syndrome. Applying the same technology to MASH was a natural extension.
The partnership with UC San Diego brought together two of the leading centers for liver disease research in the world [2]. Dr. Loomba, who had spent his career studying nonalcoholic fatty liver disease, had published more than 400 peer-reviewed papers on the topic. His clinic at UC San Diego was one of the largest referral centers for MASH patients in the country.
What the Trial Showed
The Phase IIb trial enrolled 160 adults with biopsy-confirmed MASH and mild to moderate fibrosis, stages F1 to F3. The patients were randomly assigned to receive one of three doses of ION224 or a placebo. The injections were given once a month for 51 weeks.
The primary endpoint was improvement in liver inflammation without worsening of fibrosis. Secondary endpoints included resolution of MASH, improvement in fibrosis, and changes in liver fat content measured by MRI.
The results, published in The Lancet in May 2026, showed that patients receiving the highest dose had a 60% rate of improvement in liver inflammation compared to 25% in the placebo group. Approximately 40% of patients on the highest dose achieved resolution of MASH, meaning their liver biopsies no longer showed signs of steatohepatitis.
Fibrosis improved in 35% of patients on the highest dose, compared to 15% on placebo. This was statistically significant. No previous drug had shown such a clear benefit on fibrosis in a Phase II trial.
The drug was also safe. The most common side effects were mild injection site reactions. There were no cases of severe liver toxicity. Triglyceride levels actually decreased in patients taking ION224, a finding that surprised researchers because earlier DGAT2 inhibitors had caused dangerous increases.
Dr. Loomba said the results were “unprecedented” in an interview after the data was released [1]. He noted that the drug appeared to work through a completely different mechanism than existing treatments.
The Landscape of Competing Approaches
ION224 is not the only drug in development for MASH. The field has become increasingly crowded as pharmaceutical companies race to capture a market that is expected to reach $30 billion by 2030.
Madrigal Pharmaceuticals received FDA approval for Rezdiffra in March 2024, making it the first drug specifically indicated for MASH with moderate to severe fibrosis. Rezdiffra works by activating the thyroid hormone receptor beta in the liver, which increases fat breakdown and reduces inflammation. But the drug requires daily oral dosing and has shown limited efficacy in patients with advanced fibrosis.
Novo Nordisk and Eli Lilly are testing their GLP-1 receptor agonists, semaglutide and tirzepatide, in MASH patients [6]. These drugs work primarily by promoting weight loss, which indirectly reduces liver fat. Early results have been promising, but the drugs require weekly injections and are expensive.
Intercept Pharmaceuticals tried for years to get approval for obeticholic acid, a bile acid modulator that showed some benefit in MASH but caused severe itching and elevated cholesterol levels [7]. The FDA rejected the drug twice.
Akero Therapeutics and 89bio are testing FGF21 analogs, which mimic a hormone that regulates metabolism. These drugs have shown impressive results in early trials, reducing liver fat by more than 50% in some patients.
But none of these drugs target the root cause of liver fat production the way ION224 does. The antisense approach is fundamentally different because it stops the liver from making fat in the first place, rather than trying to remove fat that has already accumulated.
The Connection to Other Fields
The technology behind ION224 has applications far beyond MASH. Antisense oligonucleotides are being tested for a wide range of diseases, from Huntington’s disease to cancer to cardiovascular disease.
At Ionis Pharmaceuticals, researchers have developed antisense drugs that target APOC3 for familial chylomicronemia syndrome, TTR for transthyretin amyloidosis, and LPA for high lipoprotein(a) [4]. The company has more than 40 drugs in its pipeline.
The key insight that made these drugs possible came from basic research at universities like Harvard, Stanford, and MIT in the 1970s and 1980s. Scientists discovered that short strands of DNA could bind to RNA and prevent it from being translated into protein. This was the foundation of antisense technology.
But turning that discovery into a drug took decades. Early antisense molecules were unstable and caused immune reactions. Researchers at Ionis and other companies had to chemically modify the molecules to make them more stable and less toxic [4]. They also had to figure out how to deliver the drugs to specific tissues, like the liver.
The liver turned out to be one of the easiest organs to target. Antisense drugs injected under the skin or into the bloodstream naturally accumulate in the liver because of the organ’s role in filtering blood. This made MASH an ideal target for antisense therapy.
The Patients Who Changed the Numbers
Among the 160 patients in the trial was a man named David Chen, a 54-year-old accountant from San Diego. David had been diagnosed with MASH five years earlier during a routine health screening. His liver enzymes were elevated. A biopsy showed F2 fibrosis.
David tried everything to reverse his condition. He lost 30 pounds. He stopped eating sugar. He exercised four times a week. His liver enzymes improved, but a follow-up biopsy showed that his fibrosis had progressed to F3.
“I was scared,” David said in an interview. “I knew what F3 meant. I knew I was heading toward cirrhosis. There was nothing else I could do.”
When David’s doctor told him about the ION224 trial, he signed up immediately. He did not know if he was getting the drug or the placebo. He just knew he had to try.
After 51 weeks, David’s biopsy showed that his fibrosis had regressed from F3 to F1. His liver fat content had dropped by 70%. His inflammation was gone.
“I felt like I got my life back,” David said. “I didn’t lose any more weight. I didn’t change my diet. The drug did all the work.”
David’s story is not unique. Many patients in the trial showed similar improvements. The data suggested that ION224 could reverse liver damage even in patients who had not responded to lifestyle changes.
The Road Ahead
The success of the Phase IIb trial has set the stage for Phase III studies, which will enroll 1,000 to 2,000 patients across multiple countries. These larger trials will need to confirm the drug’s safety and efficacy before regulators at the FDA and European Medicines Agency consider approval.
If approved, ION224 would be the first antisense therapy for MASH and the first drug that directly targets liver fat production. The potential market is enormous. Analysts estimate that more than 100 million people in the United States alone could benefit from the drug.
But challenges remain. The drug must be injected monthly, which may limit patient acceptance. The cost of antisense therapies is also high. ION224 could cost $20,000 to $50,000 per year, making it inaccessible to many patients without insurance coverage.
Dr. Loomba and his team are already thinking about combination therapies. They believe that pairing ION224 with GLP-1 agonists like semaglutide could produce even better results [6]. The liver-targeted drug would stop fat production while the weight loss drug would reduce overall body fat.
“We are entering a new era in the treatment of fatty liver disease,” Dr. Loomba said [1]. “For the first time, we have a drug that addresses the root cause. We are no longer just managing symptoms. We are stopping the disease process itself.”
The Broader Implications
The development of ION224 represents a shift in how scientists think about metabolic disease. For decades, the focus was on treating the consequences of obesity — high blood pressure, high cholesterol, diabetes. But the underlying problem, the accumulation of fat in organs where it does not belong, was largely ignored.
Fatty liver disease is just one example of this phenomenon. Fat can also accumulate in the pancreas, causing beta cell dysfunction and diabetes. It can accumulate in the heart, causing cardiomyopathy. It can accumulate in the kidneys, causing nephropathy.
The same mechanisms that drive liver fat production may also drive fat accumulation in other organs. If ION224 works in the liver, similar antisense drugs could be developed for other tissues.
Researchers at the University of Michigan are already testing antisense therapies for pancreatic steatosis. Scientists at Washington University in St. Louis are exploring drugs that target fat production in the heart. The field is expanding rapidly.
The Moment of Discovery
Dr. Loomba remembers the moment he first saw the data from the Phase IIb trial. It was late at night. He was sitting alone in his office at UC San Diego, staring at a spreadsheet on his computer screen [2].
The numbers were clear. The drug worked.
He leaned back in his chair and looked out the window. The lights of San Diego glittered in the distance. Somewhere out there, millions of people were living with a disease they did not know they had. A disease that was slowly, silently destroying their livers.
For the first time in his career, Dr. Loomba believed that he had something to offer them.
The syringe still held the same clear liquid. But now, everyone knew what it could do.
Sources
1. University of California San Diego School of Medicine
2. UC San Diego
3. University of Texas Southwestern Medical Center
5. National Institutes of Health
6. Novo Nordisk